January 13, 2026 a 12:38 pm
ELV: Analysts Ratings - Elevance Health Inc.
Elevance Health Inc., a leading player in the health benefits sector, continues to gain robust traction among analysts as evidenced by its recent ratings. The company's extensive portfolio and consistent performance have bolstered its reputation. As of recent market evaluations, analyst sentiments reflect a predominantly positive outlook, with a stable number of “Buy” and “Strong Buy” recommendations. However, attention to evolving market conditions remains crucial, as shifts in sentiment could impact future stock evaluation.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 10 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment regarding Elevance Health's stock has seen notable stability, with a consistent number of buy ratings over recent months. While "Strong Buy" recommendations have seen some fluctuations, the Hold category has experienced marginal growth. Observations indicate that the number of total analyst ratings has stabilized over the past few months.
- Strong Buy ratings have decreased from 8 to 4 over the period from mid-2024 to early 2026.
- Buy ratings have mostly remained constant, indicating steady confidence in the stock.
- Hold ratings have slightly increased, reflecting a cautious approach from some analysts.
Percentage Trends
Throughout the review period, there have been noticeable shifts in the proportional distribution of analyst recommendations. While the proportion of “Buy” ratings remains high, a modest increase in “Hold” ratings suggests analyst caution. This trend hints at potential market uncertainties or a recalibration of expectations regarding the company's performance prospects.
- Percentage of Strong Buy ratings decreased significantly from 35% in mid-2024 to approximately 17% by early 2026.
- Buy ratings have consistently represented around 40-50% of total ratings.
- Hold ratings have gradually increased, from 22% in mid-2024 to 33% in early 2026.
Latest Analyst Recommendations
| Date | New Recommendation | Previous Recommendation | Publisher |
|---|---|---|---|
| 2026-01-08 | Outperform | Peer Perform | Wolfe Research |
| 2026-01-07 | Overweight | Overweight | Wells Fargo |
| 2026-01-05 | Overweight | Overweight | Barclays |
| 2025-12-19 | Hold | Buy | Deutsche Bank |
| 2025-12-18 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Previous Recommendation | Publisher |
|---|---|---|---|
| 2026-01-08 | Outperform | Peer Perform | Wolfe Research |
| 2025-12-19 | Hold | Buy | Deutsche Bank |
| 2025-07-21 | Hold | Buy | Argus Research |
| 2025-07-18 | Market Perform | Outperform | Leerink Partners |
| 2025-04-15 | Neutral | Outperform | Baird |
Interpretation
The overall analyst sentiment towards Elevance Health Inc. suggests cautious optimism. While there is a steady stream of Buy ratings, the shift towards more Hold recommendations hints at cautiousness amid potential market unpredictability. With consistent ratings but notable changes in recommendations, it's evident that analysts are keeping a close eye on the company's performance trends and market conditions. The stability of sustained "Buy" recommendations indicates underlying confidence, yet the rise in Hold ratings suggests a measured approach, reflecting varied expectations and a need for vigilant market monitoring.
Conclusion
Elevance Health Inc. remains a robust entity in the health benefits sector with a solid foundation, reflected in a high proportion of Buy recommendations. However, increased Hold ratings reflect growing market caution. The company's ability to adapt to market changes will be crucial in maintaining its favorable analyst stance. Overall, while the potential for growth remains, so does the need for vigilance in investment strategies. As analysts balance optimism with caution, monitoring sentiment shifts will be key in gauging future opportunities and risks.